-transparent.png){kind=logo}
1. The effects of the cytochrome P450 inhibitors, proadifen, clotrimazole and 17-octadecynoic acid (17-ODYA) on K-currents in freshly-isolated single cells derived from rat portal vein and on mechanical activity in whole veins were studied. 2. When cells were stepped from -90 mV to a series of test potentials (from -80 to +50 mV), a delayed rectifier current (IK(V)) and an A-type current (IK(A)) could be identified. Proadifen (10 microM), clotrimazole (30 microM) and 17-ODYA (5 microM) each inhibited IK(V) but had little effect on IK(A). 3. When cells were held at -10 mV to inactivate the time-dependent K-currents, IK(V) and IK(A), levcromakalim (3 microM) induced a time-independent outward K-current (IK(ATP)) which was totally inhibited by clotrimazole (30 microM) and almost fully inhibited by proadifen (10 microM). 17-ODYA (5 microM) had no effect on IK(ATP) and exerted only a minor inhibitory action on this current at 20 microM. 4. 17-ODYA (5 microM) potentiated current flow through the large conductance, Ca-sensitive K-channel (BKCa). In contrast, proadifen (10 microM) had no effect on IBK(Ca) whereas clotrimazole (30 microM) exerted a small but significant inhibitory action. 5. Proadifen (10 microM) and clotrimazole (30 microM) each inhibited the magnitude but increased the frequency of spontaneous contractions in whole portal veins. 17-ODYA (5 microM) had no effect on spontaneous contractions but these were inhibited when the concentration of 17-ODYA was increased to 50 microM. 6. The spasmolytic effect of levcromakalim on spontaneous contractions was antagonized by proadifen (10-30 microM) in a concentration-dependent manner but 17-ODYA (up to 50 microM) was without effect. 7. These results in portal vein show that cytochrome P450 inhibitors exert profound effects on a variety of K-channel subtypes. This suggests that enzymes dependent on this cofactor may be important regulators of K-channel activity in smooth muscle. The relevance of these findings for the identification of the pathway involved in the synthesis of the endothelium-derived hyperpolarizing factor is discussed.
G Edwards, and
P M Zygmunt, and
E D Högestätt, and
A H Weston
January 2012,
Neuro endocrinology letters,
G Edwards, and
P M Zygmunt, and
E D Högestätt, and
A H Weston
July 1992,
British journal of pharmacology,
G Edwards, and
P M Zygmunt, and
E D Högestätt, and
A H Weston
June 2002,
Hepatology (Baltimore, Md.),
G Edwards, and
P M Zygmunt, and
E D Högestätt, and
A H Weston
July 1999,
Canadian journal of physiology and pharmacology,
G Edwards, and
P M Zygmunt, and
E D Högestätt, and
A H Weston
March 1977,
Acta physiologica Scandinavica,
G Edwards, and
P M Zygmunt, and
E D Högestätt, and
A H Weston
December 1977,
European journal of pharmacology,
G Edwards, and
P M Zygmunt, and
E D Högestätt, and
A H Weston
May 2013,
Die Pharmazie,
G Edwards, and
P M Zygmunt, and
E D Högestätt, and
A H Weston
May 1986,
British journal of pharmacology,
G Edwards, and
P M Zygmunt, and
E D Högestätt, and
A H Weston
July 2022,
Xenobiotica; the fate of foreign compounds in biological systems,
G Edwards, and
P M Zygmunt, and
E D Högestätt, and
A H Weston
October 1976,
British journal of pharmacology,
